Tag:

Eisai

Latest Headlines

Latest Headlines

Eisai's copay offer on Belviq has unintended consequences for Arena

As competition in the obesity drug space ramps up, Arena's marketing partner Eisai is rolling out a new savings card for weight-loss drug Belviq. And for the California drugmaker, that means good news and bad news for its revenue outlook.

Big Pharma threatens to sue U.K. fund as officials nix Novartis, Sanofi and Eisai meds

U.K. officials have decided which drugs to toss off the Cancer Drug Fund, which pays for drugs rejected by cost-effectiveness gatekeepers. Reportedly, Novartis, Sanofi and Eisai treatments are among them.

Arena, Eisai have to recall nearly 122,000 bottles of Belviq over labeling glitch

Arena Pharmaceuticals has seen sales of its weight-loss drug Belviq improve since teaming up with marketing partner Eisai. But the two have hit a manufacturing stumbling block, having to voluntarily recall three lots of the drug because of labeling issues.

Eisai opens new plants targeting Asia and Europe

Japanese drugmaker Eisai opened two new plants--one targeting products for Asia and the other aimed at Europe--as part of its plans to expand its global manufacturing operations.

Eisai 'speechless' after another Fycompa price smack-down from Germany

Germany's cost-effectiveness gatekeepers have delivered another blow to Eisai over the price of Fycompa. And the verdict, just the drugmaker's latest frustration over the epilepsy drug, has left it "speechless" and "dismayed."

Eisai wins FDA nod for a drug to treat chemo-caused nausea

Eisai and partner Helsinn secured the FDA's blessing to market Akynzeo, a combination treatment designed to prevent nasuea and vomiting among cancer patients undergoing chemotherapy.

Eisai adds to chemo side-effects franchise with FDA nod for Akynzeo

Months after launching a regulatory battle to extend exclusivity for two of its best-selling products, Eisai won FDA approval for its Akynzeo drug to treat common side effects in patients undergoing chemotherapy.

Top women in biotech 2014

Carving out a successful career in biopharma isn't easy, for men or women. The failure rate of experimental drugs is astronomically high. And just because a company wins an approval is no...

When is 5 years not 5 years? When it's the FDA counting, Eisai claims

What makes a 5-year exclusivity period? Under U.S. law, it's the 5 years after FDA starts the clock ticking. Eisai has no qualms about that. But the Japanese drugmaker says the agency started that clock much too soon for two of its products--and it's suing the FDA to change that.

Struggling Eisai files its thyroid cancer drug lenvatinib in U.S., EU

Still suffering from the loss of patent protection on its big Alzheimer's drug Aricept, Japan's Eisai said today that the company had fired off a pair of applications for its new cancer drug to U.S. as well as European regulators.